Arquer Diagnostics Revenue and Competitors
Estimated Revenue & Valuation
- Arquer Diagnostics's estimated annual revenue is currently $1.5M per year.
- Arquer Diagnostics's estimated revenue per employee is $251,000
Employee Data
- Arquer Diagnostics has 6 Employees.
- Arquer Diagnostics grew their employee count by -54% last year.
Arquer Diagnostics's People
Name | Title | Email/Phone |
---|---|---|
1 | Assay Development Scientist | Reveal Email/Phone |
Arquer Diagnostics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $6.1M | 49 | -18% | $10M | N/A |
#2 | $30.4M | 121 | 29% | N/A | N/A |
#3 | $139.8M | 913 | -3% | $200K | N/A |
#4 | $84.1M | 0 | N/A | $1.2M | N/A |
#5 | $43.4M | 173 | 30% | N/A | N/A |
#6 | $64.5M | 257 | 12% | N/A | N/A |
#7 | $64.3M | 205 | 26% | $129.6M | N/A |
#8 | $19.6M | 78 | -7% | N/A | N/A |
#9 | $65.8M | 262 | 7% | N/A | N/A |
#10 | $73.7M | 235 | 20% | $115.5M | N/A |
What Is Arquer Diagnostics?
Arquer Diagnostics is a private, UK based diagnostics company focused on the development and commercialisation of a non-invasive diagnostic test for bladder and prostate cancer. The test, which is based on a standard ELISA assay format, can measure in urine a protein directly involved in cell replication. The technology can be easily applied to standard lab practices or automated platforms, and has the potential to be developed into a point of care test. It also has applications beyond prostate and bladder cancer including diagnostics for multiple cancers of the urinogenitary tract, and colorectal and cervical cancer.
keywords:N/AN/A
Total Funding
6
Number of Employees
$1.5M
Revenue (est)
-54%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.5M | 7 | 75% | N/A |
#2 | $2M | 10 | 0% | N/A |
#3 | $1M | 11 | N/A | N/A |
#4 | $2.1M | 11 | N/A | N/A |
#5 | N/A | 13 | 44% | $42M |